title: Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis.
abstract: BACKGROUND
  The Japanese severity score (JSS) for acute pancreatitis was revised in 2008. As special therapies for severe acute pancreatitis (SAP), continuous regional arterial infusion of protease inhibitor and antibiotics (CRAI) and enteral nutrition (EN) are now utilized in Japan. We investigated the usefulness of the new JSS and the indications for CRAI and EN based on the new JSS.
  
  
  METHODS
  We assessed the new JSS in 138 patients with SAP according to the previous Japanese criteria. Usefulness of the new JSS for the prediction of mortality rates was compared with conventional scoring systems by receiver-operator characteristic curve analysis. We analyzed the relationship between the new JSS and prognosis in patients with and without CRAI and EN, respectively.
  
  
  RESULTS
  Forty-five patients (33%) were assessed as having mild acute pancreatitis, and 93 patients (67%) were assessed as having SAP. Their mortality rates were 7 and 40%, respectively. The area under the curve for the prediction of mortality rates with the new JSS was 0.822 and was the highest among conventional scoring systems. In patients with new JSS >or= 6, the mortality rate was lower in patients with CRAI than in patients without CRAI (P = 0.129). In patients with new JSS >or= 4, the mortality rate was lower in patients with EN than in patients without EN (P = 0.016).
  
  
  CONCLUSIONS
  The new JSS is useful and easier to use for the prediction of prognosis compared to the conventional scoring systems. EN was effective in reducing the mortality rate in patients with a new JSS >or= 4.
authors.affiliation: Department of Surgery, Kinki University School of Medicine, Osaka-sayama, Japan. daisen-ueda@key.ocn.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Ueda
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Takeyama
authors.forename: Takeo
authors.initials: T
authors.lastname: Yasuda
authors.forename: Keiko
authors.initials: K
authors.lastname: Kamei
authors.forename: Shumpei
authors.initials: S
authors.lastname: Satoi
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Sawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Shinzeki
authors.forename: Yonson
authors.initials: Y
authors.lastname: Ku
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kuroda
authors.forename: Harumasa
authors.initials: H
authors.lastname: Ohyanagi
mesh_terms: D000208:Acute Disease; D001550:Benzamidines; D004750:Enteral Nutrition; D005260:Female; D006146:Guanidines / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000145:classification* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D011480:Protease Inhibitors / Q000008:administration & dosage; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D001550:Benzamidines; D006146:Guanidines; D011480:Protease Inhibitors; C032855:nafamostat